| http://www.w3.org/ns/prov#value | - ation of the planned phase 2 clinical study of MST-188 in acute limb ischemia; the risk that, even if clinical studies are successful, the FDA or other regulatory agencies may determine they are not su'/>/>SOURCE Mast Therapeutics, Inc.Copyright??2012 PR Newswire.All rights reserved0GOODPage: 1 2 3 4 Related medicine technology :1.
|
